Cosmos Hub’s native token ATOM rose above $2.10, extending its weekly gain to around 8%. The move came as the market reacted to a newly announced partnership between Cosmos Hub and Injective. Traders appear to be treating the development as a meaningful upgrade for both liquidity conditions and cross-chain functionality within the broader Cosmos ecosystem.
USDC integration seen as a key catalyst
At the center of the partnership is the planned integration of USDC into the Cosmos Hub ecosystem. The stated goal is to improve liquidity and strengthen cross-chain interoperability. For market participants, adding a major stablecoin can improve capital movement across connected networks and make ecosystem activity more efficient. That narrative has helped reinforce bullish sentiment around ATOM in the short term.
Buyback mechanism adds support narrative
The collaboration also includes a feature that has drawn particular attention from investors: a mechanism to buy back ATOM using protocol fees generated through the Cross-Chain Transfer Protocol, or CCTP. While the long-term impact will depend on adoption and actual fee generation, the market has already started to price in the idea that this structure could offer support for the token’s value over time.
Volume spikes as technical momentum remains positive
On-chain data cited in the report shows ATOM trading volume climbing to $120.74 million, its highest level since February. That jump suggests a clear increase in trader engagement. From a technical standpoint, ATOM is still trading above important support zones, indicating that bullish momentum remains intact for now. At the same time, the Relative Strength Index (RSI) is in overbought territory, which could signal higher volatility or short-term profit-taking if momentum cools.
The next level closely watched by the market is the 200-day EMA near $2.34, identified as a major resistance area. A successful break above that level could open the door to additional upside. If the token fails to clear it, consolidation or a pullback may follow. For now, the Injective partnership has clearly put ATOM back in focus.